BPTES inhibits anthrax lethal toxin-induced inflammatory response

Area of Science:

• Immunology
• Microbiology
• Pharmacology

Background:

• Bacillus anthracis lethal toxin is a key factor in anthrax pathogenesis, inducing NLRP1b inflammasome activation and pyroptosis.
• Current therapeutic options targeting NLRP1b inflammasome are lacking for clinical use.

Purpose of the Study:

• To identify and characterize novel inhibitors of NLRP1b inflammasome activation.
• To evaluate the therapeutic potential of BPTES, a Glutaminase inhibitor, against anthrax lethal toxin-induced inflammation.

Main Methods:

• Assessed BPTES's effect on NLRP1b inflammasome activation in macrophages.
• Investigated the specificity of BPTES against other inflammasomes (NLRP3, NLRC4, AIM2).
• Elucidated the molecular mechanism of BPTES action, focusing on proteasomal degradation pathways.
• Evaluated BPTES efficacy in a murine model of anthrax lethal toxin challenge.

Main Results:

• BPTES specifically inhibited NLRP1b inflammasome activation in macrophages without affecting NLRP3, NLRC4, or AIM2.
• BPTES was found to prevent the UBR2-mediated proteasomal degradation of the NLRP1b N terminus.
• This inhibition blocked caspase-1 processing and subsequent pyroptosis.
• BPTES treatment significantly ameliorated disease progression in mice challenged with anthrax lethal toxin.

Conclusions:

• BPTES is a potent and specific inhibitor of NLRP1b inflammasome activation.
• BPTES demonstrates therapeutic potential for treating inflammatory diseases caused by Bacillus anthracis lethal toxin.
• BPTES represents a promising pharmacological candidate for future clinical development against anthrax toxin-related conditions.